---
title: "Jiuzhou Pharma's subsidiary, Pharmaceutical Technology, passed the on-site inspection by the U.S. FDA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/241566568.md"
description: "Jiuzhou Pharma's subsidiary, Zhejiang Jiuzhou Pharmaceutical Technology Co., Ltd., underwent a cGMP on-site inspection by the U.S. FDA from March 17 to 21, 2025, and passed the inspection. This inspection covered six major systems, including quality systems, materials, and production, indicating that the pharmaceutical technology meets FDA requirements, providing assurance for the company's expansion into international markets and positively impacting the global regulated market. The company has established a cGMP quality management system that complies with global standards, enhancing its overall competitiveness"
datetime: "2025-05-23T08:12:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/241566568.md)
  - [en](https://longbridge.com/en/news/241566568.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/241566568.md)
generator: "portal-rs"
---

# Jiuzhou Pharma's subsidiary, Pharmaceutical Technology, passed the on-site inspection by the U.S. FDA

According to the Zhitong Finance APP, Jiuzhou Pharma (603456.SH) announced that its subsidiary Zhejiang Jiuzhou Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Pharmaceutical Technology") underwent a cGMP (current Good Manufacturing Practice) on-site inspection by the U.S. Food and Drug Administration (hereinafter referred to as "FDA") from March 17 to March 21, 2025. The inspection covered six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls. Recently, Pharmaceutical Technology received the Establishment Inspection Report (EIR) issued by the U.S. FDA, indicating that Pharmaceutical Technology has passed this cGMP on-site inspection.

The successful completion of the U.S. FDA on-site inspection demonstrates that Pharmaceutical Technology meets the FDA's requirements in terms of drug cGMP quality management systems and production environment facilities, providing a solid guarantee for the company's continuous expansion into international markets and positively impacting the expansion of the global regulated market. At the same time, the company has established a tiered cGMP quality management system that meets globally leading industry standards for research and development, production, quality control, and project management, which has a positive driving effect on enhancing the company's overall competitiveness and future development

### Related Stocks

- [603456.CN](https://longbridge.com/en/quote/603456.CN.md)

## Related News & Research

- [Trump claims $22 trillion is pouring into the US through foreign investments — almost double what the White House estimates](https://longbridge.com/en/news/298834560.md)
- [Is Scott Bessent winning the wrong battle in markets?](https://longbridge.com/en/news/298824236.md)
- [Exploring The Competitive Space: Broadcom Versus Industry Peers In Semiconductors & Semiconductor Equipment](https://longbridge.com/en/news/299034058.md)
- [Unitree launches upgraded G1+ humanoid robot with six major upgrades](https://longbridge.com/en/news/299008304.md)
- [Abasca’s Loki flake graphite deposit makes Canada Investment Summit prospectus](https://longbridge.com/en/news/298907093.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**